Artificial Intelligence and EMA: initiatives for use in pharmacovigilance
During 2024, EMA published tools and guidelines to integrate artificial intelligence into pharmacovigilance processes. Here they are.
During 2024, EMA published tools and guidelines to integrate artificial intelligence into pharmacovigilance processes. Here they are.
During 2024, EMA Account Management, has introduced numerous new features to simplify the user experience and improve security.
In 2024, changes were made to improve the quality of data managed and the operational efficiency of the system.
The review introduces important updates relating to risk minimisation measures and their management.
Throughout 2024, the European Medicines Agency (EMA) has spearheaded a series of projects aimed at improving the management of pharmacovigilance data. Here are the main innovations.
The European Pharmacovigilance Congress is the unmissable event to discover the latest news on pharmacovigilance, from regulatory challenges to technological developments. Here are the topics of this year.
With the entry into force of the AI Act, new rules are established for medical devices based on artificial intelligence (AI).
The Rally Lana 2024 took place on July 19 and 20, attracting drivers and enthusiasts from all over the world to Biella. Once again, SafetyDrugs renewed its role as the official sponsor of this prestigious event.
The management of pharmacovigilance funds will become more efficient thanks to AIFA's new platform.
Discover the main themes of the AFI Symposium 2024, from sustainability to supply chain challenges, and explore the latest developments.
The AFI Symposium 2024, held from June 5 to 7 in Rimini, offers a significant opportunity for professionals in the pharmaceutical sector to stay updated. Here are the sessions.
Clinical trials are a fundamental phase in the development of a therapy. We have gathered essential information worth knowing about them.
In a constant effort to promote awareness of the importance of this practice, we have collected and answered the most common questions relating to pharmacovigilance.
The new AIFA Board of Directors recently announced the allocation of funds for pharmacovigilance and cybersecurity.
There are numerous events that led to the birth of pharmacovigilance. Here is its evolution from its origins to today.
AIFA has recently embarked on a process of restructuring governance to promote investments in research and development and accelerate drug approval processes.
The latest edition of SD Collection, the SafetyDrugs special with insights, updates and useful advice on pharmacovigilance is now available.
Pharmacovigilance data protection is an essential element and to guarantee security we have relied on Oracle for years.